Therefore, it seems that so far neither EGFR-TKIs nor monoclonal antibodies such as cetuximab are effective therapeutic options in glioblastoma patients, irrespective of EGFRvIII occurrence in tumor [177, 188]. Here, EGFR is linked to neoplasm.